Drawing for LIGACHEM

USPTO serial 79408203

LIGACHEM

Reviewed by CopyMark Law Group

Reg. 7910368Status 700Registered
Filing date
Status date
Registration date
Aug 26, 2025
Examiner
SWAIN, MICHELE LYNN
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with LIGACHEM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Richard Y. Kim

Richard Y. Kim Snell & Wilmer L.L.P.One East Washington Street, Suite 2700Phoenix, AZ 85004-2556United States

Goods and services

ClassDescriptionStatusFirst use
005Vaccines; food supplements; vitamin preparations; crude medicines for treating cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; nutraceuticals for use as a dietary supplement; biological preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical pharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; chemical preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical molecular diagnostic reagents for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; biopharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; syrups for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medicated lozenges for pharmaceutical purposes; capsules sold empty for pharmaceuticals; chemico-pharmaceutical preparations for pharmaceutical or medical purposes, namely, for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; antibodies for medical purposes; medical antibodies, especially antibody conjugates and active ingredients and antibody conjugates; chemical reagents for medical use, especially chemical reagents for linking molecules for medical use; pharmaceutical compositions for use in treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; plant extracts, other than essential oils, for medicinal purposes; pharmaceutical preparations for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets; pharmaceutical preparations for the treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; antibiotics; anti-cancer preparations; mixed vitamin preparations; chemotherapeutics; pharmaceutical preparations for the treatment of rare cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 16, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Apr 2, 2026FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 30, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 29, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Mar 15, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 15, 2026FIMPFINAL DISPOSITION PROCESSED—
Nov 26, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 26, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 26, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 10, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 10, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 4, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 7, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 12, 2025RFNTREFUSAL PROCESSED BY IB—
Apr 8, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 8, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 8, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 27, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 27, 2025RFRRREFUSAL PROCESSED BY MPU—
Feb 21, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 20, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 19, 2025ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Feb 19, 2025PBSRWITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST—
Feb 14, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 12, 2025DOCKASSIGNED TO EXAMINER—
Nov 12, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 12, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 8, 2024LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Oct 31, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance